TwinBeech Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

TwinBeech Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-43,735	Closed	-$314K	–	758
2025 Q3	$314K	Buy	+43,735	New	+$2.28M	0.01%	466
2024 Q3	–	Sell	-58,552	Closed	-$2.57M	–	803
2024 Q2	$2.57M	Buy	+58,552	New	+$2.48M	0.05%	306

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

TwinBeech Capital's MLTX Position: Q4 2025 in Review

TwinBeech Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 43,735 shares — an estimated $314K sold.

TwinBeech Capital first reported a position in MLTX in Q2 2024 and held it in 2 quarters. The position peaked at $2.57M in Q2 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

TwinBeech Capital reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
TwinBeech Capital sold 43,735 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $314K.
TwinBeech Capital first reported a position in MoonLake Immunotherapeutics in Q2 2024 and held it in 2 quarters.
TwinBeech Capital's MoonLake Immunotherapeutics position peaked at $2.57M in Q2 2024.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on TwinBeech Capital's 13F filing for Q4 2025, filed 17 Feb 2026.